$1.73
-0.10 (-5.46%)
Open$1.80
Previous Close$1.83
Day High$1.92
Day Low$1.73
52W High$2.68
52W Low$0.84
Volume—
Avg Volume150.0K
Market Cap8.83M
P/E Ratio—
EPS$-2.27
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,149.7% upside
Current
$1.73
$1.73
Target
$38.92
$38.92
$24.59
$38.92 avg
$51.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 555.8K | 518.1K | 501.1K |
| Net Income | 113.5K | 116.0K | 100.3K |
| Profit Margin | 20.4% | 22.4% | 20.0% |
| EBITDA | 245.4K | 221.0K | 210.9K |
| Free Cash Flow | 70.8K | 77.8K | 93.1K |
| Rev Growth | -5.3% | +6.0% | -5.8% |
| Debt/Equity | 0.43 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |